Asian markets have been navigating a complex landscape, influenced by global economic uncertainties and regional developments. As investors seek opportunities amidst these fluctuations, penny stocks—often associated with smaller or newer companies—continue to capture attention due to their low price points and potential for growth. While the term "penny stocks" might seem dated, the prospects they offer remain significant when backed by strong financials, making them an intriguing option for those looking to explore under-the-radar investment opportunities in Asia.
Top 10 Penny Stocks In Asia
| Name | Share Price | Market Cap | Rewards & Risks |
| JBM (Healthcare) (SEHK:2161) | HK$2.98 | HK$2.43B | ✅ 3 ⚠️ 1 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.50 | HK$927.78M | ✅ 4 ⚠️ 1 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.66 | HK$2.21B | ✅ 4 ⚠️ 1 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD1.35 | SGD547.14M | ✅ 4 ⚠️ 1 View Analysis > |
| T.A.C. Consumer (SET:TACC) | THB4.80 | THB2.88B | ✅ 3 ⚠️ 3 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.45 | SGD13.58B | ✅ 5 ⚠️ 1 View Analysis > |
| Ekarat Engineering (SET:AKR) | THB0.95 | THB1.4B | ✅ 2 ⚠️ 2 View Analysis > |
| Livestock Improvement (NZSE:LIC) | NZ$0.98 | NZ$139.5M | ✅ 2 ⚠️ 5 View Analysis > |
| Rojana Industrial Park (SET:ROJNA) | THB4.78 | THB9.66B | ✅ 3 ⚠️ 3 View Analysis > |
| Lum Chang Holdings (SGX:L19) | SGD0.465 | SGD174.2M | ✅ 2 ⚠️ 2 View Analysis > |
Click here to see the full list of 957 stocks from our Asian Penny Stocks screener.
Let's dive into some prime choices out of the screener.
Dawnrays Pharmaceutical (Holdings) (SEHK:2348)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company that develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally, with a market cap of HK$1.88 billion.
Operations: The company's revenue is derived from two main segments: Finished Drugs, generating CN¥1.05 billion, and Intermediates and Bulk Medicines, contributing CN¥164.60 million.
Market Cap: HK$1.88B
Dawnrays Pharmaceutical (Holdings) Limited, with a market cap of HK$1.88 billion, has faced challenges with negative earnings growth over the past year despite a 10% annual profit growth over five years. The company's short-term assets significantly exceed its liabilities, indicating strong liquidity. It maintains more cash than debt and has reduced its debt-to-equity ratio to 0.3% over five years. However, recent earnings showed a decrease in net income from CN¥493.05 million to CN¥104.57 million year-on-year for the first half of 2025, reflecting volatility in profitability despite stable revenue streams from finished drugs and intermediates segments.
- Click here to discover the nuances of Dawnrays Pharmaceutical (Holdings) with our detailed analytical financial health report.
- Gain insights into Dawnrays Pharmaceutical (Holdings)'s past trends and performance with our report on the company's historical track record.
Ju Teng International Holdings (SEHK:3336)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Ju Teng International Holdings Limited is an investment holding company that manufactures and sells casings for notebook computers and handheld devices in China and internationally, with a market cap of HK$1.42 billion.
Operations: The company generates HK$5.74 billion from its operations focused on manufacturing and selling casings for notebook computers and handheld devices.
Market Cap: HK$1.42B
Ju Teng International Holdings, with a market cap of HK$1.42 billion, has seen a decline in sales to HK$2.71 billion for the first half of 2025, alongside an increased net loss of HK$79.07 million compared to the previous year. Despite its unprofitability and negative return on equity at -13.12%, the company benefits from experienced management and board teams with average tenures of 3.6 and 8.6 years respectively. Its debt levels are satisfactory, with a net debt-to-equity ratio at 28.4%, though operating cash flow covers only 14.6% of its debt, indicating potential liquidity concerns amidst high share price volatility.
- Dive into the specifics of Ju Teng International Holdings here with our thorough balance sheet health report.
- Explore historical data to track Ju Teng International Holdings' performance over time in our past results report.
Lee's Pharmaceutical Holdings (SEHK:950)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Lee's Pharmaceutical Holdings Limited is an investment holding company that develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally with a market cap of approximately HK$1.40 billion.
Operations: The company's revenue is derived from Licensed-In Products, contributing HK$568.55 million, and Proprietary and Generic Products, which account for HK$867.89 million.
Market Cap: HK$1.4B
Lee's Pharmaceutical Holdings, with a market cap of HK$1.40 billion, has demonstrated resilience despite challenges. The company reported half-year sales of HK$694.82 million and net income of HK$67.19 million, showing growth from the previous year. Its earnings have rebounded strongly over the past year by 55.1%, surpassing industry trends, although historical declines remain a concern. The management team is experienced with an average tenure of 11 years and has maintained shareholder value without significant dilution over the past year. Despite high share price volatility, its debt is well covered by operating cash flow and it maintains more cash than total debt.
- Click to explore a detailed breakdown of our findings in Lee's Pharmaceutical Holdings' financial health report.
- Learn about Lee's Pharmaceutical Holdings' historical performance here.
Key Takeaways
- Click this link to deep-dive into the 957 companies within our Asian Penny Stocks screener.
- Interested In Other Possibilities? Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Ju Teng International Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com